Replies to post #241219 on Biotech Values

[DewDiligence]

Orlissa is hampered by the 6-month limitation like lupron (despite the data w add back people still limit use to 6 mo mostly).

Two more questions. Has the use of Orlissa’s low (150mg qD) dose, which enables 24 months of continuous treatment according to the FDA label, been discredited? Why doesn’t add-back therapy solve the BMD problem? TIA